Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Figures & data

Figure 1 PROXIMA study design.

Notes: * Patients with diagnosis of severe asthma, GINA 4, and who Need therapeutic step up.

Table 1 Baseline Characteristics of the Longitudinal Population

Characteristics	Longitudinal Population (N=123)
Sex
Female	76 (61.8%)
Male	47 (38.2%)
Race
Caucasian/White	117 (95.1%)
Black	3 (2.4%)
Asian/Oriental	3 (2.4%)
Age mean (SD)
Mean (SD)	52.7 (13.6)
Asthma duration years (SD)
Mean (SD)	19.8 (14.5)
Age at diagnosis (SD)
Mean (SD)	32.7 (15.8)
Number of exacerbations in 12-month prior enrollment
Mean (SD)	4.6 (4.1)
FEV 1
Mean (SD)	1.7 (0.7)
IgE serum level IU/Ml
Mean (SD)	409.3 (394.1)
Occupational status
Unemployed	28 (22.8%)
Employed	68 (55.3%)
Retired	27 (22.0%)
Smoking status
Non-smoker	90 (73.2%)
Former smoker	27 (22%)
Current smokers	6 (4.9%)

Figure 2 Effects of omalizumab treatment on health-related quality of life: pre-post omalizumab period comparison (EQ-5D).

Table 2 Effects of Omalizumab Treatment on Healthcare Resource Costs: Pre and Post Omalizumab Treatment Comparison

Parameters	Pre-Omalizumab	Post-Omalizumab	Δ (Post vs Pre)
Concomitant pharmacological treatments	€ 731.25	€ 346.17	-€ 385.08
Hospitalizations and ER accesses	€ 2585.68	€ 110.26	-€ 2475.42
Medical visits	€ 164.58	€ 14.38	-€ 150.20
OCS adverse events	€ 1026.86	€ 308.06	-€ 718.80
Total	€ 4508.37	€ 778.87	-€ 3729.50

Figure 3 Incremental cost-effectiveness results: sensitivity analysis.

Table 3 Incremental Cost-Effectiveness Results: Sensitivity Analysis with Increasing Discounts on Omalizumab Price

Scenario	ΔC	ΔE	ICER
Scenario 1 oma price – 20%	€ 5236.59	0.132	€ 39,807.62
Scenario 2 oma price – 25%	€ 4676.21	0.132	€ 35,547.71
Scenario 3 oma price – 30%	€ 4115.83	0.132	€ 31,287.80
Scenario 4 oma price – 35%	€ 3555.45	0.132	€ 27,027.89